Motpoly XR (Lacosamide) Patent Expiration, LOE Window & CMS Spending
Motpoly XR (Lacosamide) by Aucta: FDA Orange Book LOE 2040-06-05, 12 AB generics, $965K 2024 CMS Part D & Medicaid spend, and $1,250 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aucta |
| FDA Application & Pathway | N216185 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-06-05 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $965K |
| 2024 Medicare Part D Spend | $394K |
| 2024 Medicaid Spend | $571K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,250 intro WAC) |